30,000 Shares in Tango Therapeutics, Inc. $TNGX Bought by Guardian Partners Inc.

Guardian Partners Inc. acquired a new stake in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 30,000 shares of the company’s stock, valued at approximately $748,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in TNGX. BlackRock Inc. bought a new stake in Tango Therapeutics in the 2nd quarter worth approximately $388,826,000. TRV GP IV LLC purchased a new stake in Tango Therapeutics during the 2nd quarter valued at $120,181,383,000. Jupiter Topco LLC purchased a new stake in Tango Therapeutics during the 2nd quarter valued at $157,989,000. Seven Fleet Capital Management LP lifted its holdings in shares of Tango Therapeutics by 302.2% during the 2nd quarter. Seven Fleet Capital Management LP now owns 3,228,144 shares of the company’s stock valued at $95,661,000 after buying an additional 2,425,484 shares during the period. Finally, Jefferies Financial Group Inc. bought a new position in shares of Tango Therapeutics during the 2nd quarter valued at $62,849,000. Hedge funds and other institutional investors own 78.99% of the company’s stock.

Insider Activity

In related news, insider Jessica Newcomb sold 8,200 shares of Tango Therapeutics stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $24.22, for a total transaction of $198,604.00. Following the sale, the insider owned 59,121 shares of the company’s stock, valued at approximately $1,431,910.62. This trade represents a 12.18% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Adam Crystal sold 27,000 shares of the business’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $24.47, for a total value of $660,690.00. Following the completion of the transaction, the insider directly owned 115,743 shares in the company, valued at approximately $2,832,231.21. This represents a 18.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 6.50% of the company’s stock.

Tango Therapeutics Price Performance

Shares of Tango Therapeutics stock opened at $26.98 on Thursday. Tango Therapeutics, Inc. has a 1-year low of $6.69 and a 1-year high of $34.39. The company’s fifty day simple moving average is $23.79 and its 200-day simple moving average is $25.24. The stock has a market capitalization of $4.55 billion, a PE ratio of -31.74 and a beta of 1.17.

Tango Therapeutics (NASDAQ:TNGX) last released its earnings results on Tuesday, August 11th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.05). As a group, research analysts anticipate that Tango Therapeutics, Inc. will post -1.41 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. Wall Street Zen downgraded Tango Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Mizuho upped their price objective on Tango Therapeutics from $36.00 to $40.00 and gave the company an “outperform” rating in a research report on Friday, July 17th. HC Wainwright upped their price objective on Tango Therapeutics from $66.00 to $68.00 and gave the company a “buy” rating in a research report on Tuesday, August 18th. Weiss Ratings raised Tango Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Finally, Guggenheim increased their target price on Tango Therapeutics from $32.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Fourteen investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Tango Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $43.46.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing medicines for cancer. The company uses functional genomics and genetic screening to identify vulnerabilities in tumor cells, including dependencies created by tumor-suppressor gene loss, and to develop targeted therapies designed to selectively attack cancer cells.

Tango’s pipeline includes small-molecule programs for genetically defined solid tumors. Its lead program, TNG462, is an MTA-cooperative PRMT5 inhibitor being developed for cancers with MTAP gene deletions.